Paratek Pharmaceuticals Gross Profit

Paratek Pharmaceuticals (PRTK) currently reports a gross profit of $150M as of June 2023. That compares with $93M in the prior-year period — up 58.2% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore Paratek Pharmaceuticals's gross profit history and peer comparisons.

Paratek Pharmaceuticals's gross profit increased from $93M to $150M — a 58.2% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Paratek Pharmaceuticals's gross profit of $150M is lower than the Healthcare sector average of $66B. That is roughly 99.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Paratek Pharmaceuticals reported $150M in gross profit as of June 2023. That compares with $93M in the prior-year period — up 58.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for Paratek Pharmaceuticals, and consider following PRTK for alerts when major investors trade the stock.